v3.24.0.1
Collaboration agreements - Merck Dolaflexin Agreement (Details)
12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
target
Dec. 31, 2021
USD ($)
Sep. 30, 2023
target
Feb. 28, 2022
target
Collaboration agreements          
Collaboration revenue $ 36,855,000 $ 26,581,000 $ 43,000    
Deferred revenue 125,314,000 147,653,000 $ 3,944,000    
2014 Merck KGaA Agreement and 2018 Merck KGaA Supply Agreement          
Collaboration agreements          
Collaboration revenue 3,700,000        
Deferred revenue 0 3,900,000      
Contract assets 0 0      
2014 Merck KGaA          
Collaboration agreements          
Number of targets designated | target       6  
Johnson & Johnson Agreement          
Collaboration agreements          
Collaboration revenue 16,600,000 24,200,000      
Number of targets designated | target         3
Deferred revenue 10,400,000 15,800,000      
Contract assets 0 0      
2022 Merck KGaA Agreement          
Collaboration agreements          
Collaboration revenue 10,700,000 $ 0      
Number of targets designated | target   2      
Deferred revenue 20,200,000 $ 30,000,000      
Contract assets 0 0      
GSK Agreement          
Collaboration agreements          
Collaboration revenue 3,400,000 2,000,000      
Deferred revenue 94,600,000 98,000,000      
Contract assets $ 0 $ 0